Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
- Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use
April 15, 2024
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
- Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
- Average PMP Rate Hits Record Low at 1.2% in FY2024: MHLW
April 11, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Argenx’s gMG Therapy Vyvdura OK’ed for Self-Injection
April 11, 2024
- Label Revision Ordered for 3 Beta Blockers to Delete Contraindication in Pregnant Women
April 10, 2024
- Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
- Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
- LDP Generic League to Soon Draw Up Proposal towards Honebuto Policy
April 9, 2024
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
- Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…